特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

リキッドバイオプシー (液体生検) 市場の予測・分析 (2020-2024年) :Covid-19パンデミックの影響・癌タイプ・使用タイプ・エグゼクティブ&コンサルタントガイド

Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of Covid-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024

発行 Howe Sound Research 商品コード 939948
出版日 ページ情報 英文 385 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
リキッドバイオプシー (液体生検) 市場の予測・分析 (2020-2024年) :Covid-19パンデミックの影響・癌タイプ・使用タイプ・エグゼクティブ&コンサルタントガイド Liquid Biopsy Markets by Cancer Type and by Usage Type with Impact of Covid-19 Pandemic. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2020-2024
出版日: 2020年06月03日 ページ情報: 英文 385 Pages
担当者のコメント
がん診断、炎症疾患における検査面で主流となりつつあるリキッドバイオプシーの市場動向について、Covid-19パンデミックの影響下の中今後どのように変わっていくか、2024年度までの最新の市場分析動向をまとめた調査レポートがHowe Sound Researchより、リリースされました。
概要

癌診断の革命は、癌DNAを同定するための体外血液検査を使用して起こっています。 この技術は、血液検査であらゆるタイプの癌の広範囲にわたるスクリーニングの可能性を生み出しました。新興企業のGRAILは、一度であらゆる種類の癌を検出する血液検査を発表しました。 同社は現在、癌の早期発見を支援するために、循環セルフリーゲノムアトラス(CCGA)と呼ばれる10,000人以上の被験者研究に取り組んでいます。

当レポートでは、世界のリキッドバイオプシー (液体生検) 市場について調査し、国、癌のタイプ、および用途別による市場の分析と予測、近年の開発動向、主要企業のプロファイルなど、体系的な情報を提供しています。

第1章 イントロダクションおよび市場の定義

  • リキッドバイオプシーとは?
  • シーケンシング革命
  • 市場の定義
  • 調査手法
  • リキッドバイオプシー関連支出の見通し

第2章 市場概要

  • 動的な市場における参入企業
  • 生検の使用
    • 前癌状態
    • 炎症状態
  • 生検サイト
  • 現況:生検分析
  • 癌のエビデンス:リキッドバイオプシー技術
  • 包囲下の癌治療プロトコル
  • 業界構造

第3章 市場動向

  • 成長促進要因
    • 非侵襲的なゲームチェンジャー
    • 低いコス
    • 高い精度
    • 幅広い潜在的用途
    • 人口高齢化
  • 成長抑制要因
    • 低価格
    • 標準の欠如
    • プロトコル耐性
    • 初期導入コスト
    • COVID-19
  • 装置と自動化
  • 診断技術の開発

第4章 リキッドバイオプシーの近年の発展動向

  • 最近の発展動向:重要性・同セクションの使用方法

第5章 主要企業のプロファイル

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

第6章 リキッドバイオプシー診断の世界の市場

  • 世界市場の概要:国別
  • 世界市場の概要:癌タイプ別
  • 世界市場の概要:用途別

第7章 世界のリキッドバイオプシー診断市場:癌タイプ別

  • 乳癌
  • 大腸癌
  • 子宮頸部癌
  • 肺癌
  • 前立腺癌
  • その他の癌

第8章 世界のリキッドバイオプシー診断市場:用途別

  • シーケンシング
  • 診断
  • 治療
  • モニター

付録

図表

Table of Tables

  • Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2014 to 2024 ($Billion)
  • Table 2 Market Players by Type
  • Table 3 Biopsy Sites
  • Table 4 Advantages of Liquid Biopsy in Screening Market
  • Table 5 Outlook - Phases of Liquid Biopsy Adoption by Year
  • Table 6 Five Factors Driving Growth
  • Table 7 Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global Market by Region
  • Table 11 Global Market by Cancer
  • Table 12 Global Market by Usage
  • Table 13 Breast by Country
  • Table 14 Colorectal by Country
  • Table 15 Cervical by Country
  • Table 16 Lung by Country
  • Table 17 Prostate by Country
  • Table 18 Other by Country
  • Table 19 Screening by Country
  • Table 20 Diagnostic by Country
  • Table 21 Therapy by Country
  • Table 22 Monitor by Country
  • Table 23 2020 Clinical Lab Fee Schedule
  • Table 24 COVID -19 Approved Assays

Table of Figures

  • Figure 1 Medicare Clinical Lab Expenditures 2014 to 2024 ($Million)
  • Figure 2 Comparison of Liquid Biopsy Classes
  • Figure 3 Characteristics of Different Vesicle Types
  • Figure 4 Percentage of World Population Over 65
  • Figure 5 Global Market Density Chart
  • Figure 6 Global Market by Cancer - Base vs. Final
  • Figure 7 Global Market by Cancer Base Year
  • Figure 8 Global Market by Cancer End Year
  • Figure 9 Cancer Share by Year
  • Figure 10 Cancer Segments Growth
  • Figure 11 Global Market by Usage - Base vs. Final
  • Figure 12 Global Market by Usage Base Year
  • Figure 13 Global Market by Usage End Year
  • Figure 14 Usage Share by Year
  • Figure 15 Usage Segments Growth
  • Figure 16 Breast Growth
  • Figure 17 Colorectal Diagnostics Growth
  • Figure 18 Cervical Growth
  • Figure 19 Lung Growth
  • Figure 20 Prostate Growth
  • Figure 21 Other Growth
  • Figure 22 Screening Growth
  • Figure 23 Diagnostic Growth
  • Figure 24 Therapy Growth
  • Figure 25 Monitor Growth
目次

OVERVIEW:

The Screening, Diagnostic, Therapy Selection, Recurrence Monitoring and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread SCREENING FOR ALL TYPES OF CANCERS WITH A BLOOD TEST.

GRAIL, a new company with impressive backing, has announced a single blood test to detect all cancers. The company is now working on a 10,000-plus subject study, called the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. The technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures. The market is still in its infancy but has JUST MOVED OUT OF THE DEVELOPMENT PHASE AND INTO THE GROWTH PHASE. The impact on the health care industry is enormous. The report forecasts the market size out to 2024. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Liquid Biopsy Market - Strategic Situation Analysis & Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 What is Liquid Biopsy?
  • 1.2 The Sequencing Revolution
  • 1.3 Market Definition
    • 1.3.1 Revenue Market Size
  • 1.4 Methodology
    • 1.4.1 Authors
    • 1.4.2 Sources
  • 1.5 A Spending Perspective on Liquid Biopsy
    • 1.5.1 An Historical Look at Clinical Testing

2. Market Overview

  • 2.1 Players in a Dynamic Market
    • 2.1.1 Academic Research Lab
    • 2.1.2 Diagnostic Test Developer
    • 2.1.3 Genomic Instrumentation Supplier
      • 2.1.3.1 Cell Separation and Viewing Instrumentation Supplier
    • 2.1.4 Pharmaceutical/Reagent Supplier
    • 2.1.5 Independent Testing Lab
    • 2.1.6 Public National/regional lab
    • 2.1.7 Hospital lab
    • 2.1.8 Physician Lab
    • 2.1.9 Audit Body
    • 2.1.10 Certification Body
  • 2.2 Using Biopsies
    • 2.2.1 Cancer
    • 2.2.2 Precancerous conditions
    • 2.2.3 Inflammatory conditions
  • 2.3 Biopsy Sites
  • 2.4 The Situation Today - Biopsy Analysis
  • 2.5 Evidence of Cancer - Liquid Biopsy Technology
    • 2.5.1 The Big Picture on Liquid Biopsy Technology
    • 2.5.2 The Role of CTCs
      • 2.5.2.1 Types of CTCs
      • 2.5.2.2 CellSearch Detection- Ultimate Sensitivity
      • 2.5.2.3 Epic Sciences Detection- Imaging Takes the Lead
      • 2.5.2.4 Maintrac Detection - The Microscope
      • 2.5.2.5 Other Methods
    • 2.5.3 ctDNA - Going Mainstream?
    • 2.5.4 Exosomes and Micro Vesicles - New Kid on the Block
    • 2.5.5 The Multiple Play
  • 2.6 Cancer Treatment Protocol Under Siege
    • 2.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
    • 2.6.2 The Cancer Screening Market Opportunity
      • 2.6.2.1 GRAIL - What Is It?
    • 2.6.3 Cancer Management vs. Diagnosis
      • 2.6.3.1 The Role of Risk Assessment
      • 2.6.3.2 Managing Therapy
      • 2.6.3.3 Monitoring Disease - What Is It?
    • 2.6.4 Phases of Adoption - Looking into The Future
    • 2.6.5 The Promise of Liquid Biopsy
  • 2.7 Structure of Industry Plays a Part
    • 2.7.1 Hospital Testing Share
    • 2.7.2 Economies of Scale
      • 2.7.2.1 Hospital vs. Central Lab
    • 2.7.3 Physician Office Lab's
    • 2.7.4 Physician's and POCT

3. Market Trends

  • 3.1 Factors Driving Growth
    • 3.1.1 Non Invasive Game Changer
    • 3.1.2 Lower Cost
    • 3.1.3 Greater Accuracy
    • 3.1.4 Wide Range of Potential Uses
    • 3.1.5 Aging Population
  • 3.2 Factors Limiting Growth
    • 3.2.1 Lower prices
    • 3.2.2 Lack of Standards
    • 3.2.3 Protocol Resistance
    • 3.2.4 Initial Adoption Cost
    • 3.2.5 COVID-19
  • 3.3 Instrumentation and Automation
    • 3.3.1 Instruments Key to Market Share
    • 3.3.2 Bioinformatics Plays a Role
  • 3.4 Diagnostic Technology Development
    • 3.4.1 Next Generation Sequencing Fuels a Revolution
    • 3.4.2 Impact of NGS on pricing
    • 3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
    • 3.4.4 CGES Testing, A Brave New World
    • 3.4.5 Biochips/Giant magneto resistance based assay

4. Liquid Biopsy Recent Developments

  • 4.1 Recent Developments - Importance and How to Use This Section
    • 4.1.1 Importance of These Developments
    • 4.1.2 How to Use This Section
      • NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
      • Liquid Biopsy Shows Promise as Screen for Cancers
      • Inivata launches RaDaR™ for the detection of residual disease and recurrence
      • Liquid Biopsy Assay Detects 50+ Types of Cancer
      • Liquid Biopsy Study Confirms Concordance with Tissue Biopsy
      • Guardant Health Liquid Biopsy Expands Medicare Coverage
      • Aethlon Medical Lands Grant for Exosome Isolation Device
      • Biolidics to Develop Liquid Biopsy Breast Cancer Test
      • Liquid Biopsy Equal to Tissue to Indicate Immunotherapy Response
      • Exact Sciences buys Genomic Health
      • Multi-Gene Liquid Biopsy Breast Cancer Panel
      • Bio-Techne receives FDA breakthrough device for prostate cancer liquid biopsy
      • Thrive to Develop Earlier Detection of Multiple Cancer Types
      • Guardant Health Liquid Biopsy Test to be Covered by EviCore
      • Liquid biopsy combines Illumina's 'ultradeep' sequencing with Grail's machine learning
      • Biocept Partnership Offering for Liquid Biopsy Adds Several Key Services
      • Natera Commercializes Tumor Whole Exome Sequencing from Plasma
      • Sienna Buys Liquid Biopsy & Exosome Isolation Technology
      • Inivata Completes £39.8M Series B Funding Round
      • Bio-Rad Clinical ddPCR Test, Diagnostic System Get FDA Clearance
      • CellMax, Medigen Biotech Partner in Colorectal Cancer Clinical Trials
      • Biodesix Acquires Integrated Diagnostics
      • Predicine, Kintor Pharmaceuticals Partner on Clinical Trials, CDx
      • Bio-Techne to Acquire Exosome Dx for Up to $575M
      • GRAIL Announces Data on Detection of Early-Stage Lung Cancers
      • Precision for Medicine Acquires ApoCell
      • NeoGenomics to Acquire Genoptix for Cash, Stocks
      • PGDx Liquid Biopsy Assay to be Used in Cancer Drug Study
      • Liquid Biopsy IDs More NSCLC Mutations in Study of Guardant Test
      • Inivata Gets Draft Medicare Coverage Determination for Lung Cancer Test

5. Profiles of Key Players

  • Abbott Diagnostics
  • AccuraGen Inc
  • Acuamark Diagnostics
  • Admera Health, LLC
  • Agena Bioscience, Inc
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagenode Diagnostics
  • Diagnologix LLC
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd
  • Genomic Health
  • GILUPI Nanomedizin
  • Grail, Inc.
  • Guardant Health
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Molecular MD
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Oxford Nanopore Technologies
  • Perkin Elmer
  • Personal Genome Diagnostics
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Quidel
  • Rarecells SAS
  • RareCyte
  • Resolution Biosciences, Inc
  • Roche Molecular Diagnostics
  • Screencell
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • SRI International
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc.
  • Thrive Earlier Detection
  • Trovagene
  • Volition

6. The Global Market for Liquid Biopsy Diagnostics

  • 6.1 Global Market Overview by Country
    • 6.1.1 Table - Global Market by Country
    • 6.1.2 Chart - Global Market by Country
  • 6.2 Global Market by Cancer - Overview
    • 6.2.1 Table - Global Market by Cancer
    • 6.2.2 Chart - Global Market by Cancer - Base/Final Year Comparison
    • 6.2.3 Chart - Global Market by Cancer - Base Year
    • 6.2.4 Chart - Global Market by Cancer - End Year
    • 6.2.5 Chart - Global Market by Cancer - Share by Year
    • 6.2.6 Chart - Global Market by Cancer - Segments Growth
  • 6.3 Global Market by Usage - Overview
    • 6.3.1 Table - Global Market by Usage
    • 6.3.2 Chart - Global Market by Usage - Base/Final Year Comparison
    • 6.3.3 Chart - Global Market by Usage - Base Year
    • 6.3.4 Chart - Global Market by Usage - End Year
    • 6.3.5 Chart - Global Market by Usage - Share by Year
    • 6.3.6 Chart - Global Market by Usage - Segments Growth

7. Global Liquid Biopsy Diagnostic Markets - By Cancer

  • 7.1 Breast
    • 7.1.1 Table Breast - by Country
    • 7.1.2 Chart - Breast Growth
  • 7.2 Colorectal
    • 7.2.1 Table Colorectal - by Country
    • 7.2.2 Chart - Colorectal Growth
  • 7.3 Cervical
    • 7.3.1 Table Cervical - by Country
    • 7.3.2 Chart - Cervical Growth
  • 7.4 Lung
    • 7.4.1 Table Lung - by Country
    • 7.4.2 Chart - Lung Growth
  • 7.5 Prostate
    • 7.5.1 Table Prostate - by Country
    • 7.5.2 Chart - Prostate Growth
  • 7.6 Other
    • 7.6.1 Table Other - by Country
    • 7.6.2 Chart - Other Growth

8. Global Liquid Biopsy Diagnostic Markets - by Usage

  • 8.1 Screening
    • 8.1.1 Table Screening - by Country
    • 8.1.2 Chart - Screening Growth
  • 8.2 Diagnostic
    • 8.2.1 Table Diagnostic - by Country
    • 8.2.2 Chart - Diagnostic Growth
  • 8.3 Therapy
    • 8.3.1 Table Therapy - by Country
    • 8.3.2 Chart - Therapy Growth
  • 8.4 Monitor
    • 8.4.1 Table Monitor - by Country
    • 8.4.2 Chart - Monitor Growth

Appendices

  • I. United States Medicare System: 2020 Clinical Laboratory Fees Schedule
  • II. COVID-19 Approved Assays